TMEM85 Inhibitors
TMEM85 inhibitors pertain to a class of chemical compounds designed to modulate the activity of the transmembrane protein 85 (TMEM85). This protein is one of the many that populate the vast and intricate landscape of cellular membranes, playing roles in various cellular processes. The inhibitors targeting TMEM85 are part of an emerging focus within biochemical research that seeks to understand and manipulate the function of membrane proteins. These inhibitors are typically small molecules that can cross the cell membrane to interact directly with TMEM85, affecting its structural conformation or hindering its interaction with other molecular entities. The specificity of these inhibitors is crucial since it ensures minimal off-target effects, which is a common challenge when dealing with proteins that may have homologous structures or similar binding sites within a cell.
The development of TMEM85 inhibitors involves rigorous biochemical and structural analysis to elucidate the protein's binding sites and conformational dynamics. Advanced techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and cryo-electron microscopy can be employed to gain insights into the three-dimensional structure of TMEM85, which is essential for the rational design of inhibitors. Once potential binding sites are identified, a combination of computational modeling and medicinal chemistry is used to create molecules that fit precisely into these sites, effectively inhibiting the protein's function. The design process is iterative, with initial hits being refined to improve their efficacy and specificity. The interaction between TMEM85 inhibitors and the protein can also be studied in live cells using various biochemical assays that can monitor the consequences of inhibition on the cellular level. These assays contribute to our fundamental understanding of TMEM85's role within the cell and how its activity can be modulated by small molecules.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A potent inhibitor of phosphoinositide 3-kinases (PI3K), LY294002 blocks the PI3K/AKT signaling pathway. TMEM85, being a transmembrane protein, could be affected by changes in PI3K activity due to its potential role in regulating intracellular signaling cascades. Inhibition of PI3K leads to decreased AKT phosphorylation and activity, which could in turn affect the functional activity of TMEM85. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin specifically inhibits mTOR (mechanistic target of rapamycin), which is a central protein in regulating cell growth and metabolism. Since TMEM85 may be involved in processes that are regulated by mTOR signaling, the inhibition of mTOR could lead to the decreased functional activity of TMEM85. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
As a selective inhibitor of ROCK (Rho-associated protein kinase), Y-27632 disrupts actin cytoskeleton organization and cell motility. TMEM85's activity could be indirectly inhibited if it is involved in cellular processes that require actin cytoskeleton dynamics, as ROCK signaling is crucial in these processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK, which is involved in stress and inflammatory responses. Should TMEM85 play a role in p38 MAPK mediated pathways, its functional activity could be indirectly inhibited by SB203580 through the downregulation of p38 MAPK activity. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 is a proteasome inhibitor that prevents the degradation of proteins marked for destruction by ubiquitin. If TMEM85 is regulated by proteasomal degradation, MG132 could lead to an indirect inhibition of TMEM85's functional activity by preventing its turnover. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), SP600125 could inhibit TMEM85 if the protein is part of JNK signaling pathways. JNK is involved in controlling a number of cellular processes, including apoptosis and inflammation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor, more potent and irreversible compared to LY294002. It would similarly lead to decreased AKT phosphorylation and potentially affect TMEM85 functional activity if TMEM85's activity is linked to the PI3K/AKT pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which is upstream of ERK in the MAPK pathway. If TMEM85 is involved in the ERK/MAPK pathway, inhibition of MEK by PD98059 would lead to a decrease in TMEM85 activity. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $103.00 $293.00 $465.00 | 15 | |
Go6983 is a broad-spectrum protein kinase C (PKC) inhibitor. If TMEM85 is involved in signaling processes that require PKC activity, the inhibition of PKC by Go6983 would lead to decreased TMEM85 activity. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
Bafilomycin A1 is a specific inhibitor of the vacuolar-type H+-ATPase (V-ATPase). If TMEM85's function is linked to endosomal or lysosomal acidification, which is regulated by V-ATPase, its inhibition could lead to decreased TMEM85 activity. | ||||||